Dipeptide Diaminobutyroyl Benzylamide Diacetate
Also referenced as: SYN-AKE
A synthetic peptide-like cosmetic ingredient with a venom-inspired design rationale.
- Evidence grade
- EExperimental / Limited Evidence
Experimental / Limited Evidence
- Regulatory status
- Not FDA Approved
A cosmetic ingredient, not an FDA-approved anti-aging drug. Cosmetic marketing and ingredient safety reviews do not establish injectable safety or therapeutic approval.
- Human data
- No
No registered clinical trials identified
- Last reviewed
- October 27, 2026
Overview
A synthetic peptide-like cosmetic ingredient with a venom-inspired design rationale.
A cosmetic ingredient, not an FDA-approved anti-aging drug. Cosmetic marketing and ingredient safety reviews do not establish injectable safety or therapeutic approval.
A venom-inspired structure does not establish muscle paralysis through intact skin.
Why It's Being Studied
- Wrinkle appearance
- Cosmetic signalling
Mechanism of Action
It was designed around a neuromuscular signalling hypothesis; it is neither snake venom nor an established clinical neuromuscular medicine.
It was designed around a neuromuscular signalling hypothesis; it is neither snake venom nor an established clinical neuromuscular medicine. A venom-inspired structure does not establish muscle paralysis through intact skin.
Skin remodelling and the hair cycle
Tap each stage to see what happens.
Background: Skin & Hair Research
Skin and hair research looks at collagen synthesis, wound closure, pigmentation and the hair-follicle cycle.
Topical cosmetic research is often industry-funded and small. Injected use of cosmetic peptides has little human data.
Research Areas & Routes Studied
- Wrinkle appearance
- Cosmetic signalling
- Topical cosmetic formulations
Evidence Summary
Cosmetic marketing is more extensive than independently verified standalone human efficacy evidence.
Higher tiers carry more weight. Filled tiers have evidence for Dipeptide Diaminobutyroyl Benzylamide Diacetate; tap to read it.
No evidence at this tier is summarised for Dipeptide Diaminobutyroyl Benzylamide Diacetate. Absence of data is not evidence of safety or benefit.
2 cited sources.
- Narrative review1
- Regulatory document1
Evidence limitations
- Cosmetic marketing is more extensive than independently verified standalone human efficacy evidence.
Reported Adverse Events in Research
- Skin sensitivity is possible; systemic and injectable safety cannot be inferred from topical use.
Limitations of Current Evidence
- A venom-inspired structure does not establish muscle paralysis through intact skin.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Was the product topical or injected?
- Were results measured by instruments or by photos and self-assessment?
- Who funded the study?
- Cosmetic claims face a lower evidence bar than medical claims.
- Pigmentation-affecting compounds carry documented risks, including changes in moles.
- Anagen
- The active growth phase of a hair follicle.
- Dermis
- The skin layer beneath the surface that holds collagen.
- Melanocortin
- A hormone family that affects pigmentation and appetite.
Compare With Other Compounds
| Dipeptide Diaminobutyroyl Benzylamide Diacetate | GHK-Cu | |
|---|---|---|
| Evidence grade | E — Experimental / Limited Evidence | C — Early Human Research |
| Regulatory status | Not FDA Approved | Not FDA Approved |
| Human data | No | Limited |
| Clinical trials | None identified | None identified |
| Research routes | Topical cosmetic formulations | Topical, Intradermal (cosmetic research) |
| Cited sources | 2 | 2 |
Frequently Asked Questions
Research References
- Narrative review
Cosmetic peptide research and delivery limitations
- Regulatory document
FDA: cosmetics are not preapproved medicines